Exploration Capital, LLC has demonstrated a consistent buying pattern focused exclusively on Fresh Tracks Therapeutics, Inc. (FRTX), with no selling activity across its 41 reported transactions. Since late March 2024, the firm has deployed $961,836 in cumulative purchases, with its most aggressive acquisitions occurring in concentrated bursts. Two high-value transactions—$300,156 on June 7 and $149,363 on May 1—account for nearly half of its total investment, supplemented by mid-sized purchases like $67,867 on May 16 and $46,471 on March 27. Smaller, incremental buys—ranging from $69 to $15,217—have occurred weekly, suggesting ongoing accumulation rather than isolated positioning.
The activity reveals a singular focus on FRTX, with no diversification across other holdings in recent months. June’s purchases—$81,014 on June 10 following the June 7 buy—indicate sustained interest despite the stock’s volatility. The absence of any sales, coupled with the repeated acquisitions at varying price points, points to a deliberate buildup. While the scale of individual transactions fluctuates significantly, the directional bias is unambiguous: Exploration Capital has been a net buyer with no apparent profit-taking or rebalancing in this position over the observed period.
AI-assisted summary